FADE IN:



|FADE IN: |Suggested Lead: |

|SLATE |Breast cancer is the third deadliest form of cancer in the United States. Each |

| |year, more than 200,000 women are diagnosed with breast cancer, and this year |

| |alone, almost 40,000 women are expected to die of the disease. As October is |

| |National Breast Cancer Awareness Month, now is an important time to take a |

| |serious look at how you and your loved ones can fight this devastating disease.|

| |XX has more in this report: |

| |NARRATOR: For more than two decades, 62-year-old Nita Beth Camp, a passionate |

|VT- Nita Beth preparing dinner, teaching |advocate for better science education in Texas public schools, battled advanced|

| |breast cancer. While she is a walking success story today, she endured a long,|

| |hard battle. |

| | |

|Nita Beth Camp SOT |NITA BETH CAMP SOT: : I had a mastectomy then after that I had chemotherapy. |

| |After my chemotherapy or during my chemotherapy my hair fell out, I lost a |

| |great deal of weight down to about 90 pounds. Then after remission, my weight |

|Visual of Xeloda vials and tablets |returned. |

|VT- Nita Beth taking medicine at home |NARRATOR: About that time, Nita Beth’s doctor started her on an oral |

| |chemotherapy in the form of a pill, called Xeloda. Taken together with another|

| |chemotherapy drug, Taxotere, Xeloda has proven effective in treating patients |

| |with metastatic breast cancer who’ve failed anthracycline-containing treatment.|

| | |

| |DR. VUKELJA SOT: Xeloda is a novel pill-form of chemotherapy that was designed |

|VT- Dr. Vukelja, Associate Director for Breast Cancer, U.S. |to target cancer cells. However, Xeloda isn’t right for all patients. And, |

|Oncology Center |like all anti-cancer drugs, Xeloda has some potentially serious side effects |

|Dr. Vukelja SOT |that patients should discuss with their doctor. |

| |NARRATOR: While Nita Beth began to improve, another battle was beginning. In |

|VT- Elizabeth |2001, Nita Beth’s daughter, Elizabeth, 38, a successful attorney, was diagnosed|

| |with early stage breast cancer and was subsequently treated successfully with |

| |radiation. |

| |NITA BETH CAMP SOT: “Elizabeth wanted to have a mammogram because of my history|

|Nita Beth Camp SOT |but because she was so young her doctor was hesitant to do one. But she was |

| |insistant, the doctor finally gave in and thank god she the doctor did because |

| |she’s fine today. |

|VT - Nita Beth and Elizabeth | |

| |NARRATOR: For now, both Nita Beth and her daughter are cancer free as a result |

| |of early detection, being proactive about their concerns, consulting with their|

|Nita Beth Camp SOT |doctor to find appropriate treatment options and, above all, having hope. |

|VT – Nita Beth speaking with other cancer patients | |

| |NITA BETH CAMP SOT: : I tell patients to stay positive, to not be afraid. The |

| |worst thing that you can do is to concentrate on your fears and let that get in|

| |your way of recovery. You need to be an advocate of yourself. Patients need |

| |to take an active role in their healthcare. |

| |SUGGESTED ANCHOR TAG: To get more information about Xeloda visit or |

|VT -- Scrolled |call Roche at 1-800-526-6367. |

| | |

| | |

| |Indications in Metastatic Breast Cancer: |

| | |

| |Breast Cancer Combination Therapy: XELODA in combination with docetaxel is |

| |indicated for the treatment of patients with metastatic breast cancer after |

| |failure of prior anthracycline-containing chemotherapy. |

| |Breast Cancer Monotherapy: XELODA monotherapy is also indicated for the |

| |treatment of patients with metastatic breast cancer resistant to both |

| |paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to|

| |paclitaxel and for whom further anthracycline therapy is not indicated, eg, |

| |patients who have received cumulative doses of 400 mg/m2 of doxorubicin or |

| |doxorubicin equivalents. Resistance is defined as progressive disease while on |

| |treatment, with or without an initial response, or relapse within 6 months of |

| |completing treatment with an anthracycline-containing adjuvant regimen. |

| | |

| |Important Safety Information: |

| | |

| |WARNING |

| |For patients receiving Xeloda and warfarin concomitantly, frequent monitoring |

| |of INR or prothrombin time (PT) is recommended. A clinically important drug |

| |interaction between Xeloda and warfarin has been demonstrated. Altered |

| |coagulation parameters and/or bleeding and death have been reported. |

| |Clinically significant increases in PT and INR have been observed within days |

| |to months after starting Xeloda, and infrequently within one month of stopping |

| |Xeloda. Age greater than 60 and a diagnosis of cancer independently predispose|

| |patients to an increased risk of coagulopathy. |

| |Xeloda is contraindicated in patients who have a known hypersensitivity to |

| |capecitabine or to any of its components or to 5-fluorouracil. Xeloda is |

| |contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) |

| |deficiency. Xeloda is also contraindicated in patients with severe renal |

| |impairment. |

| |Patients with moderate renal impairment require dose reduction. Xeloda can |

| |induce diarrhea, sometimes severe. Patients with severe diarrhea should be |

| |carefully monitored. Patients ≥80 years old receiving Xeloda monotherapy, and |

| |patients ≥60 years old receiving Xeloda in combination with docetaxel, may |

| |experience a greater incidence of grade 3 or 4 adverse events. Xeloda may |

| |cause fetal harm when given to a pregnant woman. Women of childbearing |

| |potential should be advised to avoid becoming pregnant while receiving |

| |treatment with Xeloda. |

| |In Xeloda monotherapy for metastatic breast cancer, the most common adverse |

| |events ((10%) were lymphopenia (94), anemia (72), diarrhea (57), hand-foot |

| |syndrome (57), nausea 93), fatigue (41), vomiting (37), dermatitis (37), |

| |neutropenia (26), thrombocytopenia (24), stomatitis (24), anorexia (23), |

| |hyperbilirubinemia (22), paresthesia (21), abdominal pain (20), eye irritation |

| |(15), constipation (15), and pyrexia (12). |

| |In combination therapy with Xeloda and docetaxel for metastatic breast cancer, |

| |the most common adverse events ((10%) were lymphocytopienia (99), leukopenia |

| |(91), neutropenia/granulocytopenia (86), anemia (80), diarrhea (67), stomatitis|

| |(67), hand-foot syndrome (63), nausea (45), alopecia (41), threombocytopenia |

| |(41), vomiting (35), edema (33), abdominal pain (30), pyrexia (28), asthenia |

| |(26), fatigue (22), constipation (20), hyperbilirubinemia (20), neutropenic |

| |fever (16), weakness (16), taste disturbance (16), headache (15), arthralgia |

| |(15) , myalgia (15), dyspepsia (14), nail disorder (14), dyspnea (14), pain in |

| |limb (13), anorexia (13), cough (13), back pain (12), dizziness (12), |

| |paresthesia (12), lacrimation increased (12), sore throat (12), appetite |

| |decreased (10), and dehydration (10). |

| | |

| |I’m XX reporting. |

Additional B-Roll:

Images of people undergoing intravenous chemotherapy

Lab footage

Manufacturing footage

Dr. Vukelja walking through clinic

Nita Beth enjoying time with her daughter

Nita Beth speaking to teachers about the importance of a better science curriculum

Nita Beth speaking to other breast cancer patients

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download